Author Archives: Michelle Janas

Perfusion’s Role in Maintenance of High-Density T-Cell Cultures

T-cell therapy is a rapidly growing field of personalized medicine, attracting the interest of venture capitalists and pharmaceutical companies alike. Such therapies exploit T cells’ innate abilities to protect against pathogens as well as to seek and destroy cancerous cells. Although many different forms of T-cell therapies are currently in clinical trials, they all follow a common protocol: T cells are isolated from a patient, modified and expanded in a laboratory setting, and then infused back into the same patient…

Optimization of the Rocking Speed and Angle of a Perfusion Bioreactor for T Cell Culture

For autologous T cell therapy to be effective, T cells sampled from a patient need to be grown in sufficient quantity before being injected back. The typical cell number required for an 80 kg patient is 8.109 cells. Achieving such a dose with T flasks, while maintaining cell health, poses logistical challenges that can become intractable when the number of patients rises. This is why the Xuri™ Cell expansion system W5, a rocking platform which enables automated high cell density…